Bridging the divide between discovery and delivering patient-specific medicines is the goal of many biotech companies. Our unique approach utilises Tay Therapeutics’ technology platform coupled to in-house discovery and development expertise to deliver substantial improvements in patient care.
![Squiggle Graphic](wp-content/uploads/squiggle.png)
LATEST NEWS
June 13, 2024
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
June 5, 2024
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201